Health Trials

Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression

ConditionsChronic Kidney DiseasesAcute Kidney InjuryKidney Failure
Trial statusNot yet recruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18-90
SponsorEbima Clifford Okundaye

About this trial

Chronic kidney disease CKD is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the United States alone. CKD is a contributor to illness and is associated with a diminished quality of life and reduced life expectancy . In this study the investigators are using a novel drug to target improved function of the kidneys.

Eligibility criteria

Qualifiers

Inclusion criteria

Patient with Chronic kidney disease

Estimated Glomerular function by MDRD of less than 60mls/min

Patients with declining renal function ( as measured by eGFR by MDRD )

Disqualifiers

Symptomatic renal failure

Presence of any suspected Acute renal failure superimposed

Presence of cast , hematuria, or abnormal urinalysis outside of simple UTI

No known reversible cause of renal decline

Trial design

Treatments tested in this trial

  • QRX-3

Treatment groups

3,000 Participants
are divided into 2 treatment groups

Locations

1

Map coordinates are unavailable for these locations. Locations are shown below instead.

Neukidney Inc Status unavailable 77504, Pasedena, TexasUnited StatesUnited States

Sponsors and collaborators

Ebima Clifford Okundaye

Lead sponsor

Neukidney Inc.

Sponsor institution

Source ClinicalTrials.gov